Abstract
Biliary tract carcinoma (BTC) is a common malignancy in human digestive system. The lethality of BTC is essentially attributed to the asymptomatic growth of BTC and the lack of effective diagnostic options. The disease is therefore usually detected at an advanced stage and lost the opportunity of surgical therapy. Conventional chemotherapy and radiation therapy have been notably ineffective against BTC. There is now a real and urgent need to focus on developing novel and potent therapeutic strategies against BTC. Human epidermal growth factor receptor 2/ neu (HER2/ neu) is a member of the ErbB receptor tyrosine kinase family. HER2/ neu is associated with tumor proliferation, invasion, and metastasis that would impact in a significant way on clinical outcome. HER/ neu may become a new therapy target of BTC. Key words: Biliary tract neoplasms, malignancy; Human epidermal growth factor receptor 2/ neu; Therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
